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Introduction: Non small cell lung carcinoma (NSCLC) is a non-immu-
nogenic cancer. Unlike in melanomas, tumor inﬁltrating lymphocytes 
of the effector cell phenotype are not present in the tumor. NSCLC 
tumor cells thus have never been exposed to effector cells and, unlike 
melanoma, have not been selected to resist cytotoxic T lymphocyte 
(CTL) attack. Would NSCLC tumors be able to resist CTL, if CTL are 
generated by vaccination?
We designed two types allogeneic, whole cell NSCLC vaccines, gener-
ated from an NSCLC cell line (AD100) established in Miami and con-
ditioned to continuous growth in standard cell culture media. Genomic 
analysis of the morphological types of NSCLC, including squameous 
carcinoma, show largely overlapping genetic up- and downregulation 
of several hundred genes in the different cell types (1).
The B7- vaccine: The AD100 cell line was cotransfected with CD80 
(B7.1) and HLA A1 to render the cells immunogenic. Cells are irradi-
ated to prevent replication, but remain alive for several days when 
placed in culture. The in vivo immunogenicity of the vaccine is based 
on B7.1 expression which stimulates NK cell activation. 
Allogenicity and HLA A1 expression prevents engagement of killer 
inhibitory receptors (KIR) and inhibition of NK mediated cytotoxity. 
NK activation and killing of vaccine cells produces IFN- γ and releases 
tumor antigens. Dendritic cells and macrophages are attracted and take 
up released tumor antigens and cross present them to CD8 T cells dif-
ferentiating into CTL.
In a phase I study 19 patients were enrolled with stage IIIB/IV NSCLC 
who had failed several lines of prior therapy. They were treated by 
intracutaneous injection of 5x107 AD100-HLAA-B7.1 cells every 
two weeks for a maximum of nine vaccinations. The vaccine was safe 
causing no vaccine related serious adverse event. The immune response 
was measured by analyzing puriﬁed CD8 cells stimulated in vitro 
with vaccine cells for IFN-γ production by Elispot assays. All but one 
patient had a signiﬁcant immune responses. The mean response after 
three vaccinations was the generation of 160 NSCLC speciﬁc CD8 
CTL per ml of blood from a pre-immunization level of 0-1 CTL/ml. 
After 6 and 9 vaccinations the NSCLC speciﬁc CTL level increased to 
220 CTL/ml. One year survival was 47%, two year survival 32%. Six 
patients had a clinical response, rated as stable disease in 5 patients and 
a minor response in one.
Although uncontrolled the study showed a deﬁnite trend towards clini-
cal beneﬁt of B7 vaccination. We are currently conducting two phase II 
studies to determine effectiveness and to study the clinical response in 
patients with undetectable disease after surgery and chemotherapy.
The gp96-vaccine: Gp96 is the one of the major protein and peptide 
chaperones of the endoplasmatic reticulum. It transports peptides on 
their way to MHC class I presentation and helps folding of membrane 
associated and secreted proteins during synthesis. Srivastava was the 
ﬁrst (2)to show that gp96 isolated from tumor cells and injected into 
syngeneic mice was able to induce a tumor speciﬁc immune response 
that was able to protect mice from a subsequent challenge with the 
same tumor but not against other tumors. Gp96 is taken up by dendritic 
cells and macrophages via its endocytic receptor CD91 and causes acti-
vation of DC, independent of CD4 help and CD40-L/CD40 interaction. 
Uptake of gp96 and its chaperoned peptides results in cross presen-
tation of the peptides by MHC I of the DC and priming of antigen 
speciﬁc cognate CD8 T cells.
To render gp96 suitable for a vaccine system with allogeneic cells, we 
genetically modiﬁed the protein by deleting its endoplasmatic reticulum 
retention signal and replacing it with the Fc portion of IgG1 (3). Gp96-
Ig transfected tumor cells secrete gp96-Ig along with its chaperoned 
peptides. Injection of gp96-Ig transfected tumor cells into syngeneic 
mice results in tumor rejection associated with the clonal expansion of 
cognate CD8-CTL to a frequency of 15-40 of all CD8 cells (4). Clonal 
CD8 CTL expansion is enhanced in CD4 deﬁcient mice while CD40-L 
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deﬁcient mice expand CD8 similar to w.t. mice. The combined knock 
out of B7.1 and B7.2 completely abrogates CD8 expansion while the 
loss of either of the single genes reduces expansion to about 50% of 
w.t. NKT cells are not required but NK cells enhance CD8 CTL re-
sponses. Antigen cross presentation and cross priming of cognate CD8 
cells is ~20 million fold enhanced when peptides are chaperoned by 
gp96 compared to their presence as intact protein, as measured with the 
ovalbumin TCR transgenic system.
Following the events after intraperitoneal injection of tumors secret-
ing gp96-Ig, we found that gp96-secretion promotes recruitment of 
monocyte/macrophages, dendritic cells and NK cells. DC and NK cells 
become activated only when gp96 is secreted by the injected tumor 
cells leading to local CD8 CTL expansion followed by systemic expan-
sion. Lymphotoxin-α k.o. mice have no peripheral lymph nodes includ-
ing mesenteric lymph nodes and Peyer’s patches, however they are able 
to support gp96-Ig mediated CD8 CTL expansion to a similar extent as 
wild type mice. Using the ovalbumin as surrogate antigen, alllogeneic 
tumor cells transfected with ovalbumin and gp96-Ig are able to mediate 
cognate CD8 CTL (OT-I) expansion to the same extent as syngeneic 
cells. Gp96-Ig deliverd by allogeneic tumor cells thus has many proper-
ties that make it suitable for vaccine purpose.
We have cotransfected the AD100 NSCLC line with HLA A1 and 
gp96-Ig. One million cells secrete 400ng gp96-Ig within 24h in tissue 
culture. Upon irradiation with 12,000 rad the cells continue to secrete 
gp96-Ig at declining rates for the next two weeks in culture. In the 
phase I study that has just opened we will enroll 24 patients with stage 
IIIB/IV NSCLC who have failed at least two lines of prior therapy. The 
vaccination schedule and analysis is similar to that described above for 
the B7 vaccine. Early results will be reported.
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Extensive stage small cell lung cancer (SCLC) is an incurable, aggres-
sive form of lung cancer with little improvement in outcome over the 
past 2 decades. SCLC tumor cells frequently express a mu-tant form 
of the p53 protein, which is far more stable than wild type p53, and 
therefore over-expressed. This differential over-expression as compared 
to normal cells provides the basis for the proposed tumor vaccine. The 
dependence of tumor cells on abnormal p53 expression for their sur-
vival makes this an “ideal” candidate for cancer immunotherapy, as the 
emergence of antigen-loss variants is not possible. We have developed 
a new vaccine based on transduction of dendritic cells (DC) with wild-
type p53 using an adenoviral construct. This vaccine demonstrated 
potency in pre-clinical experiments. Based on those observation we 
initiated a phase I/II clinical trial that was designed to test the safety 
and efﬁcacy of the Ad.p53-DC vaccine in patients who have extensive 
stage SCLC. 
Between January 2003 and June 2006, 54 patients with extensive stage 
small cell lung cancer were enrolled into trial. Patients were treated 
with platinum based ﬁrst-line chemotherapy to best response and those 
patients with stable disease or minor progression but retaining ECOG 
performance status of 0 or 1 underwent leukapheresis 8 weeks after the 
last dose of chemotherapy. DC were generated from peripheral blood 
precursors and then infected with adenoviral construct containing wild-
type p53 (ADVEXIN). The number of p53 positive DCs was evaluated 
using ﬂow cytometry. Patients received 3 doses of vaccine i.d. (2-5x106 
p53+ DCs per dose). If patients had stable disease or better, they were 
given 3 more doses of the vaccine monthly. 
No serious adverse events attributable to the vaccine occurred. No he-
matologic nor organ toxicity occured, and no autoimmunity developed. 
To evaluate immunological response, samples of peripheral blood were 
collected before immunization, 2-3 weeks after completion of 3 rounds 
of immunization and 2 months after completion of immunization. p53 
speciﬁc immune responses were evaluated in ELISPOT assay using ca-
narypox virus (ALVAC) containing wild-type p53 or empty vector us-
ing an automated ELISPOT reader (CTL). Response to vaccination was 
considered signiﬁcant if a p53-speciﬁc response after immunization 
(2-3 weeks after 3rd vaccine) was more than 2 SD higher than the p53-
speciﬁc response before immunization and at least 2 SD higher than the 
response to control ALVAC. Immune responses were further evalu-
ated in a subset of 12 HLA-A2 positive patients, using p53-derived or 
control peptides presented by HLA-A2. Signiﬁcant p53 speciﬁc T cell 
responses to vaccination were found in 41.9% of all treated patients. 
The pre-vaccination level of p53-speciﬁc immunity was similar in pa-
tients who responded immunologically to the vaccine to those who did 
not respond. We also analyzed the possible link between the number 
of DCs injected with each vaccine and p53 speciﬁc immune re-sponse 
developed as the result of immunization. No correlation between the 
number of injected DCs and p53-speciﬁc immune response was found. 
The level of anti-p53 antibody did not correlate with the development 
of p53-speciﬁc T-cell response or clinical response to vaccination. Anti-
adenovirus antibodies could potentially play a critical role in limiting 
the effectiveness of adenovirus based cancer vaccines. Most patients 
had a detectable pre-immunization level of anti-Adv IgG antibody. 
After three rounds of immunization with Adv-p53 DC, the titer of anti-
Adv antibody increased in 16 of 28 tested patients (57.1%). A moderate 
in-crease (>2 and <8 fold) was observed in 14 patients and a substantial 
(>8-fold) increase in 2 pa-tients. Both patients with the substantial in-
crease in anti-adenovirus antibodies did not develop p53-speciﬁc T-cell 
responses to immunization, wheares such were observed in 12 out of 14 
patients (85.7%) who had a moderately increased titer of anti-Adv anti-
bodies, and in only 5 out of 13 pa-tients (38.5%) who had no detectable 
increase in antibody titer (p = 0.018). The anti-adenovirus antibodies 
detected in those patients had neutralizing activity.
The generation of a p53-speciﬁc T-cell response depends not only on 
the quality of antigen stimulation but also on the functional activity of 
T-cells and antigen presenting cells in the host, speciﬁcally DCs. Our 
experiments demonstrated that immunological response to vaccination 
did not correlate with functional activity of DCs, T cells or the presence 
of regulatory T cells. Since myeloid derived suppressor cells (MDSC) 
